BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poupon RE, Poupon R, Balkau B. Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis. N Engl J Med 1994;330:1342-7. [DOI: 10.1056/nejm199405123301903] [Cited by in Crossref: 337] [Cited by in F6Publishing: 77] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Rosmorduc O, Poupon R. [Hepatobiliary transporters: from genomics to diseases]. Gastroenterol Clin Biol 2004;28:D112-20. [PMID: 15213671 DOI: 10.1016/s0399-8320(04)94995-0] [Reference Citation Analysis]
2 Heathcote J. Autoimmune cholangitis. Gut. 1997;40:440-442. [PMID: 9176067 DOI: 10.1136/gut.40.4.440] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
3 Usami J. Primary Biliary Cholangitis-associated Palmar Keratosis. Intern Med 2021;60:2877. [PMID: 33746168 DOI: 10.2169/internalmedicine.6919-20] [Reference Citation Analysis]
4 Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med. 2017;32:213-228. [PMID: 28171717 DOI: 10.3904/kjim.2016.268] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
5 Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda M. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci. 1996;41:809-815. [PMID: 8674405 DOI: 10.1007/BF02213140] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
6 Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review. J R Soc Med 1997;90 Suppl 31:6-12. [PMID: 9204005 DOI: 10.1177/014107689709031s03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Fairfield B, Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep 2021;3:100220. [PMID: 33598648 DOI: 10.1016/j.jhepr.2020.100220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, DePaoli AM. NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Hepatol Commun. 2018;2:1037-1050. [PMID: 30202819 DOI: 10.1002/hep4.1209] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 12.5] [Reference Citation Analysis]
9 Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10(6): 894-898 [PMID: 15040040 DOI: 10.3748/wjg.v10.i6.894] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
10 Hirschfield GM, Al-Harthi N, Heathcote EJ. Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol. 2009;2:11-28. [PMID: 21180531 DOI: 10.1177/1756283x08098966] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Mazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci. 2015;72:1631-1650. [PMID: 25511198 DOI: 10.1007/s00018-014-1805-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 8.8] [Reference Citation Analysis]
12 Pausch J, Gatzen M. [Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?]. Internist (Berl) 2006;47:1239-40, 1242-4. [PMID: 17077981 DOI: 10.1007/s00108-006-1732-6] [Reference Citation Analysis]
13 Nathanson MH, Burgstahler AD, Masyuk A, Larusso NF. Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochem J. 2001;358:1-5. [PMID: 11485545 DOI: 10.1042/0264-6021:3580001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 1.3] [Reference Citation Analysis]
14 Liberal R, Grant CR. Cirrhosis and autoimmune liver disease: Current understanding. World J Hepatol 2016; 8(28): 1157-1168 [PMID: 27729952 DOI: 10.4254/wjh.v8.i28.1157] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
15 Harms MH, de Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Trivedi PJ, Hirschfield GM, Pares A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Hansen BE, Buuren HRV, van der Meer AJ. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut 2020;69:1502-9. [PMID: 31843787 DOI: 10.1136/gutjnl-2019-319057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
16 Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut. 1996;39:475-478. [PMID: 8949657 DOI: 10.1136/gut.39.3.475] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 2.8] [Reference Citation Analysis]
17 Oh B, Choi WS, Park SB, Cho B, Yang YJ, Lee ES, Lee JH. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract 2016;70:302-11. [PMID: 26997458 DOI: 10.1111/ijcp.12790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Ali AH, Tabibian JH, Lindor KD. Update on pharmacotherapies for cholestatic liver disease. Hepatol Commun 2017;1:7-17. [PMID: 29404429 DOI: 10.1002/hep4.1013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
19 Schlichting J, Leuschner U. Drug therapy of primary biliary diseases: classical and modern strategies. J Cell Mol Med 2001;5:98-115. [PMID: 12067457 DOI: 10.1111/j.1582-4934.2001.tb00144.x] [Reference Citation Analysis]
20 Amaya MJ, Nathanson MH. Calcium signaling in the liver. Compr Physiol 2013;3:515-39. [PMID: 23720295 DOI: 10.1002/cphy.c120013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
21 Mulinacci G, Palermo A, Invernizzi P, Carbone M. Old and novel prognostic biomarkers in primary biliary cholangitis. Expert Opinion on Orphan Drugs 2021;9:123-31. [DOI: 10.1080/21678707.2021.1927700] [Reference Citation Analysis]
22 Corpechot C, Poupon R, Chazouillères O. New treatments/targets for primary biliary cholangitis. JHEP Rep 2019;1:203-13. [PMID: 32039371 DOI: 10.1016/j.jhepr.2019.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
23 Baki JA, Tapper EB. Contemporary Epidemiology of Cirrhosis. Curr Treat Options Gastroenterol 2019;17:244-53. [PMID: 30949926 DOI: 10.1007/s11938-019-00228-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
24 Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020;51:90-109. [PMID: 31762074 DOI: 10.1111/apt.15579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
25 Rodrigues MA, Gomes DA, Nathanson MH. Calcium Signaling in Cholangiocytes: Methods, Mechanisms, and Effects. Int J Mol Sci. 2018;19. [PMID: 30563259 DOI: 10.3390/ijms19123913] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lee JY, Danford CJ, Trivedi HD, Tapper EB, Patwardhan VR, Bonder A. Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci 2019;64:2338-50. [PMID: 30632051 DOI: 10.1007/s10620-019-5457-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
27 Burns J, Davenport M. Adjuvant treatments for biliary atresia. Transl Pediatr 2020;9:253-65. [PMID: 32775244 DOI: 10.21037/tp.2016.10.08] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
28 Zhu GQ, Shi KQ, Huang S, Huang GQ, Lin YQ, Zhou ZR, Braddock M, Chen YP, Zheng MH. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Medicine (Baltimore) 2015;94:e609. [PMID: 25789951 DOI: 10.1097/MD.0000000000000609] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
29 Zein CO, Lindor KD. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Gastroenterol Rep. 2010;12:13-22. [PMID: 20425480 DOI: 10.1007/s11894-009-0079-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
30 D'Amato D, De Vincentis A, Malinverno F, Viganò M, Alvaro D, Pompili M, Picciotto A, Palitti VP, Russello M, Storato S, Pigozzi MG, Calvaruso V, De Gasperi E, Lleo A, Castellaneta A, Pellicelli A, Cazzagon N, Floreani A, Muratori L, Fagiuoli S, Niro GA, Feletti V, Cozzolongo R, Terreni N, Marzioni M, Pellicano R, Pozzoni P, Baiocchi L, Chessa L, Rosina F, Bertino G, Vinci M, Morgando A, Vanni E, Scifo G, Sacco R, D'Antò M, Bellia V, Boldizzoni R, Casella S, Omazzi B, Poggi G, Cristoferi L, Gerussi A, Ronca V, Venere R, Ponziani F, Cannavò M, Mussetto A, Fontana R, Losito F, Frazzetto E, Distefano M, Colapietro F, Labanca S, Marconi G, Grassi G, Galati G, O'Donnell SE, Mancuso C, Mulinacci G, Palermo A, Claar E, Izzi A, Picardi A, Invernizzi P, Carbone M, Vespasiani-Gentilucci U; Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep 2021;3:100248. [PMID: 33681748 DOI: 10.1016/j.jhepr.2021.100248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 von Schönfeld J, Breuer N, Goebell H. [Primary biliary cirrhosis: diagnosis and therapy]. Med Klin (Munich) 1998;93:627-8. [PMID: 9849055 DOI: 10.1007/BF03042679] [Reference Citation Analysis]
32 Saffioti F, Gurusamy KS, Eusebi LH, Tsochatzis E, Davidson BR, Thorburn D. Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011648. [PMID: 28350426 DOI: 10.1002/14651858.CD011648.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
33 Falcão AS, Silva RF, Vaz AR, Gomes C, Fernandes A, Barateiro A, Tiribelli C, Brites D. Cross-talk between neurons and astrocytes in response to bilirubin: adverse secondary impacts. Neurotox Res 2014;26:1-15. [PMID: 24122290 DOI: 10.1007/s12640-013-9427-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
34 Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, Iino S, Makino I, Okita K, Toda G, Tanikawa K, Kumada H; Japanese C-Viral Hepatitis Network. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007;56:1747-53. [PMID: 17573387 DOI: 10.1136/gut.2007.120956] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
35 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
36 Nathanson MH, Burgstahler AD, Mennone A, Dranoff JA, Rios-Velez L. Stimulation of bile duct epithelial secretion by glybenclamide in normal and cholestatic rat liver. J Clin Invest. 1998;101:2665-2676. [PMID: 9637700 DOI: 10.1172/jci2835] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
37 Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360:2544-2555. [PMID: 19458352 DOI: 10.1056/nejmoa0810440] [Cited by in Crossref: 451] [Cited by in F6Publishing: 224] [Article Influence: 34.7] [Reference Citation Analysis]
38 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 93] [Cited by in F6Publishing: 69] [Article Influence: 23.3] [Reference Citation Analysis]
39 Fiorucci S, Mencarelli A, Palazzetti B, Del Soldato P, Morelli A, Ignarro LJ. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc Natl Acad Sci USA. 2001;98:2652-2657. [PMID: 11226294 DOI: 10.1073/pnas.041603898] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 3.6] [Reference Citation Analysis]
40 Genda T, Ichida T, Sakisaka S, Sata M, Tanaka E, Inui A, Egawa H, Umeshita K, Furukawa H, Kawasaki S. Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system. J Gastroenterol. 2014;49:324-331. [PMID: 23478939 DOI: 10.1007/s00535-013-0782-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
41 Suri JS, Danford CJ, Patwardhan V, Bonder A. Mortality on the UNOS Waitlist for Patients with Autoimmune Liver Disease. J Clin Med 2020;9:E319. [PMID: 31979326 DOI: 10.3390/jcm9020319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lim AG, Jazrawi RP, Northfield TC. The ursodeoxycholic acid story in primary biliary cirrhosis. Gut 1995;37:301-4. [PMID: 7590420 DOI: 10.1136/gut.37.3.301] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
43 Johnson AM, Akpan EJ, Kale S, Patel A. A Rare Case Presentation: Diagnosing Primary Biliary Cholangitis in a Male Patient With Concomitant Type 1 Diabetes. Cureus 2021;13:e16109. [PMID: 34367753 DOI: 10.7759/cureus.16109] [Reference Citation Analysis]
44 Kouroumalis E, Notas G. Primary biliary cirrhosis: From bench to bedside. World J Gastrointest Pharmacol Ther 2015; 6(3): 32-58 [PMID: 26261733 DOI: 10.4292/wjgpt.v6.i3.32] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
45 Carbone M, Lleo A, Sandford RN, Invernizzi P. Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol. 2014;44:945-954. [PMID: 24481870 DOI: 10.1002/eji.201344270] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
46 Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl. 2005;11:1252-1257. [PMID: 16184542 DOI: 10.1002/lt.20511] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
47 Lim AG, Northfield TC. Ursodeoxycholic acid and primary biliary cirrhosis. BMJ 1994;309:491-2. [PMID: 8086896 DOI: 10.1136/bmj.309.6953.491] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
48 Bateson MC, Gedling P. Ursodeoxycholic acid therapy for primary biliary cirrhosis. A 10-year British single-centre population-based audit of efficacy and survival. Postgrad Med J 1998;74:482-5. [PMID: 9926123 DOI: 10.1136/pgmj.74.874.482] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
49 Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW. A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale. Hepatol Commun 2018;2:484-91. [PMID: 29761165 DOI: 10.1002/hep4.1173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
50 Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable Rare Dis Res 2012;1:66-80. [PMID: 25343075 DOI: 10.5582/irdr.2012.v1.2.66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
51 Fujita K, Nomura T, Morishita A, Shi T, Oura K, Tani J, Kobara H, Tsutsui K, Himoto T, Masaki T. Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis. J Clin Med 2019;8:E1258. [PMID: 31430975 DOI: 10.3390/jcm8081258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
52 Amaya MJ, Nathanson MH. Calcium signaling and the secretory activity of bile duct epithelia. Cell Calcium 2014;55:317-24. [PMID: 24612866 DOI: 10.1016/j.ceca.2014.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
53 Kubota J, Ikeda F, Terada R, Kobashi H, Fujioka S, Okamoto R, Baba S, Morimoto Y, Ando M, Makino Y, Taniguchi H, Yasunaka T, Miyake Y, Iwasaki Y, Yamamoto K. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol 2009;44:1000-6. [PMID: 19562250 DOI: 10.1007/s00535-009-0090-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
54 Xiang X, Yang X, Shen M, Huang C, Liu Y, Fan X, Yang L. Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Can J Gastroenterol Hepatol 2021;2021:6691425. [PMID: 33542908 DOI: 10.1155/2021/6691425] [Reference Citation Analysis]
55 Kim KA, Jeong SH. The diagnosis and treatment of primary biliary cirrhosis. Korean J Hepatol. 2011;17:173-179. [PMID: 22102382 DOI: 10.3350/kjhep.2011.17.3.173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
56 Mells GF, Jones DE. Stratified medicine and primary biliary cholangitis. Lancet Gastroenterol Hepatol 2017;2:319-21. [PMID: 28397694 DOI: 10.1016/S2468-1253(17)30047-X] [Reference Citation Analysis]
57 Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005;28:135-45. [PMID: 15879619 DOI: 10.1385/CRIAI:28:2:135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
58 Mohr L, Heintges T, Hensel F, Niederau C, Häussinger D. Treatment of autoimmune cholangitis. Dig Dis Sci 1998;43:2160-3. [PMID: 9753287 DOI: 10.1023/a:1018840105188] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
59 Setchell KD, Rodrigues CM, Podda M, Crosignani A. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut 1996;38:439-46. [PMID: 8675100 DOI: 10.1136/gut.38.3.439] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.3] [Reference Citation Analysis]
60 Tanakaa A, Leung PS, Young HA, Gershwin ME. Toward solving the etiological mystery of primary biliary cholangitis. Hepatol Commun 2017;1:275-87. [PMID: 29057387 DOI: 10.1002/hep4.1044] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
61 Palmela I, Correia L, Silva RF, Sasaki H, Kim KS, Brites D, Brito MA. Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study. Front Neurosci 2015;9:80. [PMID: 25821432 DOI: 10.3389/fnins.2015.00080] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
62 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
63 Mehal WZ, Schuppan D. Antifibrotic therapies in the liver. Semin Liver Dis. 2015;35:184-198. [PMID: 25974903 DOI: 10.1055/s-0035-1550055] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
64 van de Meeberg PC, Portincasa P, Wolfhagen FH, van Erpecum KJ, VanBerge-Henegouwen GP. Increased gall bladder volume in primary sclerosing cholangitis. Gut. 1996;39:594-599. [PMID: 8944571 DOI: 10.1136/gut.39.4.594] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
65 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
66 Koulentaki M, Moscandrea J, Dimoulios P, Chatzicostas C, Kouroumalis EA. Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci. 2004;49:1190-1195. [PMID: 15387345 DOI: 10.1023/b:ddas.0000037811.48575.da] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Trivedi HD, Lizaola B, Tapper EB, Bonder A. Primary biliary cholangitis: new treatments for an old disease. Frontline Gastroenterol 2017;8:29-36. [PMID: 28839882 DOI: 10.1136/flgastro-2016-100741] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
68 Moscoso CG, Steer CJ. "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics. Hepat Med 2019;11:109-29. [PMID: 31565001 DOI: 10.2147/HMER.S213397] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L, Lim R, Trembling P, Williamson K. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63:930-950. [PMID: 26223498 DOI: 10.1002/hep.28017] [Cited by in Crossref: 168] [Cited by in F6Publishing: 137] [Article Influence: 24.0] [Reference Citation Analysis]
70 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
71 Combes B, Markin RS, Wheeler DE, Rubin R, West AB, Mills AS, Eigenbrodt EH, Maddrey WC, Munoz SJ, Garcia-Tsao G, Bonner GF, Boyer JL, Luketic VA, Shiffman ML, Peters MG, White HM, Zetterman RK, Carithers RL Jr. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999;30:602-5. [PMID: 10462363 DOI: 10.1002/hep.510300315] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
72 Wu H, Chen C, Ziani S, Nelson LJ, Ávila MA, Nevzorova YA, Cubero FJ. Fibrotic Events in the Progression of Cholestatic Liver Disease. Cells 2021;10:1107. [PMID: 34062960 DOI: 10.3390/cells10051107] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Aldersley MA, O'Grady JG. Hepatic disorders. Features and appropriate management. Drugs 1995;49:83-102. [PMID: 7705218 DOI: 10.2165/00003495-199549010-00007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
74 Wong KA, Bahar R, Liu CH, Bowlus CL. Current Treatment Options for Primary Biliary Cholangitis. Clin Liver Dis 2018;22:481-500. [PMID: 30259848 DOI: 10.1016/j.cld.2018.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
75 Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF, Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni M, Miele L, Marra F, Giannini E, Gaudio E, Ronca V, Bonato G, Cristoferi L, Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the UK–PBC Consortium. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol 2018;3:626-34. [PMID: 30017646 DOI: 10.1016/S2468-1253(18)30163-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
76 Zhang S, Yu M, Guo F, Yang X, Chen Y, Ma C, Li Q, Wei Z, Li X, Wang H, Hu H, Zhang Y, Kong D, Miao QR, Hu W, Hajjar DP, Zhu Y, Han J, Duan Y. Rosiglitazone alleviates intrahepatic cholestasis induced by α-naphthylisothiocyanate in mice: The role of circulating 15-deoxy-Δ12,14 -PGJ2 and Nogo. Br J Pharmacol 2020;177:1041-60. [PMID: 31658492 DOI: 10.1111/bph.14886] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
77 Sato S, Miyake T, Tobita H, Oshima N, Ishine J, Hanaoka T, Amano Y, Kinoshita Y. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. World J Gastroenterol 2009; 15(22): 2782-2786 [PMID: 19522030 DOI: 10.3748/wjg.15.2782] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
78 Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004;10:894-898. [PMID: 15040040 DOI: 10.1016/s0270-9139(03)80786-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Coleman JP, Kirby LC, Setchell KD, Hylemon PB, Pandak M, Heuman DM, Vlahcevic ZR. Metabolic fate and hepatocyte toxicity of reverse amide analogs of conjugated ursodeoxycholate in the rat. J Steroid Biochem Mol Biol 1998;64:91-101. [PMID: 9569014 DOI: 10.1016/s0960-0760(97)00138-6] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
80 Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998;101:2790-2799. [PMID: 9637713 DOI: 10.1172/jci1325] [Cited by in Crossref: 381] [Cited by in F6Publishing: 104] [Article Influence: 15.9] [Reference Citation Analysis]
81 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
82 Vaz AR, Cunha C, Gomes C, Schmucki N, Barbosa M, Brites D. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol Neurobiol 2015;51:864-77. [PMID: 24848512 DOI: 10.1007/s12035-014-8731-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
83 Kolaric TO, Nincevic V, Kuna L, Duspara K, Bojanic K, Vukadin S, Raguz-Lucic N, Wu GY, Smolic M. Drug-induced Fatty Liver Disease: Pathogenesis and Treatment. J Clin Transl Hepatol 2021;9:731-7. [PMID: 34722188 DOI: 10.14218/JCTH.2020.00091] [Reference Citation Analysis]
84 Angulo P, Dickson E. Reply. Gastroenterology 1999;117:1512-3. [DOI: 10.1016/s0016-5085(99)70319-7] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
85 Zhu GQ, Huang S, Huang GQ, Wang LR, Lin YQ, Wu YM, Shi KQ, Wang JT, Zhou ZR, Braddock M, Chen YP, Zhou MT, Zheng MH. Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. Oncotarget 2015;6:24533-49. [PMID: 26109432 DOI: 10.18632/oncotarget.4528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
86 Okamoto R, Yamamoto K, Yabushita K, Okano N, Shimada N, Matsumura S, Mizuno M, Higashi T, Tsuji T. T cell repertoire in primary biliary cirrhosis: a common T cell clone and repertoire change after treatment. J Clin Immunol 2001;21:278-85. [PMID: 11506198 DOI: 10.1023/a:1010983325927] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
87 Yanguas-Casás N, Barreda-Manso MA, Nieto-Sampedro M, Romero-Ramírez L. Tauroursodeoxycholic acid reduces glial cell activation in an animal model of acute neuroinflammation. J Neuroinflammation 2014;11:50. [PMID: 24645669 DOI: 10.1186/1742-2094-11-50] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
88 Ali AH, Carey EJ, Lindor KD. Targets and investigative treatments for primary biliary cholangitis. Expert Opinion on Orphan Drugs 2016;4:1011-20. [DOI: 10.1080/21678707.2016.1227240] [Reference Citation Analysis]
89 Patel R, Portone G, Lambert JA, Mak S, Alrubaiy L. Disease-modifying therapies and symptomatic management for primary biliary cholangitis. Br J Hosp Med (Lond) 2021;82:1-9. [PMID: 34817254 DOI: 10.12968/hmed.2021.0247] [Reference Citation Analysis]